Furthermore, we found that CB is a promising anti-tumor agent that reduced FOXO1-suppressed DDP resistance by antagonizing the FOXO1-interactive protein MYH9 and its-modulated signals in NPC. This evidence concerns the gene MYH9 and neoplasm.